Q2 2026 Alivus Life Sciences Ltd Earnings Call Transcript
Key Points
- Alivus Life Sciences Ltd (BOM:543322) reported a 16% year-on-year revenue growth for Q2 FY26, driven by strong performance in the non-GPL business, which grew by 39.7% due to successful new product launches.
- The company's gross margin improved to 57.7%, up 210 basis points year-on-year, supported by rationalized input costs and a favorable product mix.
- EBITDA margin for the quarter increased to 33%, up 480 basis points year-on-year, reflecting better product mix and new launches.
- The company remains net debt-free with strong cash flow from operations of INR148 crores in Q2 FY26 and cash and cash equivalents of INR653 crores as of September 30, 2025.
- Alivus Life Sciences Ltd (BOM:543322) has a robust pipeline with 586 DMF and CEP filings globally, and a high potent API portfolio with 26 products in development, representing a total addressable market of $66 billion.
- The GPL segment experienced a decline due to customer inventory rationalization, which moderated overall growth.
- The CDMO business performance was soft in the quarter, although a rebound is expected in the second half of FY26.
- CapEx spending was slower than anticipated in the first half of FY26, with only INR115 crores spent, and the company does not expect to utilize the full INR600 crores budgeted for the year.
- The company faced a temporary slowdown in existing CDMO projects, impacting current performance.
- There was an incident involving a flash fire at a facility, leading to a penalty from the Gujarat State Pollution Board, although it was described as a one-off event.
Ladies and gentlemen, good morning, and welcome to the Alivus Life Sciences Limited Q2 FY26 earnings call. (Operator Instructions) Please note that this conference is being recorded.
I now hand the conference over to Ms. Soumi Rao from Alivus Life Sciences Limited. Thank you, and over to you, ma'am.
Good morning, everyone. I welcome you all to the earnings call of Alivus Life Sciences Limited for the quarter ended September 30, 2025. From Alivus Life Sciences, we have with us Dr. Yasir Rawjee, our MD and CEO; and Mr. Tushar Mistry, our CFO.
Our Board has approved the results for the quarter ended September 30, 2025. We have released the same to the stock exchanges and uploaded it on our website. Please note that the recording and the transcript of this call will be available on the website of the company.
Now I'd like to draw your attention to the fact that some of the information shared as part of this call, especially information with
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
